A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
NCT07546760
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Hepatic Impairment
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- September 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Research Site · Chandler, AZ
California · 1
- Research Site · Rialto, CA
Florida · 1
- Research Site · Miami Lakes, FL
Texas · 1
- Research Site · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.